Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - Bionovo

Drug Profile

Research programme: cancer therapeutics - Bionovo

Alternative Names: AA102; BN-AM-206; BN-DI-110; BN-EJ-111; BN-GS-107; BN-LJ-114; BN-PC-201; BN-PL-203; BN-RU-119; BN-SA-204; BN-SG-102; BN107; BN108; VS 101

Latest Information Update: 20 Jan 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bionovo
  • Class
  • Mechanism of Action Apoptosis stimulants; MTORC1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 12 Mar 2012 BN 107 and BN 108 are still in preclinical trials for Breast cancer in USA
  • 30 Dec 2009 Pharmacodynamics data from a preclinical trial in Breast cancer released by Bionovo
  • 05 Oct 2009 Preclinical development is ongoing in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top